NCT05580458View on ClinicalTrials.gov

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

225

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

February 1, 2027

Study Completion Date

October 1, 2027

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Shingrix

Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH